Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

NCT05725018 is registered in ClinicalTrials.gov with Abeona Therapeutics, Inc as lead sponsor.

NCT NCT05725018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05725018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Lead sponsor
Abeona Therapeutics, Inc
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 2, 2023
Completion date
September 30, 2025
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa, rdeb, recessive dystrophic epidermolysis bullosa